tiprankstipranks
Novo Nordisk price target lowered to $105 from $156 at BMO Capital
The Fly

Novo Nordisk price target lowered to $105 from $156 at BMO Capital

BMO Capital lowered the firm’s price target on Novo Nordisk (NVO) to $105 from $156 but keeps an Outperform rating on the shares. The company’s anticipated CagriSema – a drug that was supposed to best – Zepbound Phase 3 data readout failed to meet investor expectations on efficacy and tolerability and cuts the company’s margin of error for execution in 2025, the analyst tells investors in a research note. BMO adds however that the downside reaction for Novo Nordisk shares was overdone.

Don't Miss Our Christmas Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App